Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
Publication/Presentation Date
10-20-2017
Abstract
Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC. Methods In this open-label, multicenter (n = 13), parallel-arm, phase II study ( ClinicalTrials.gov identifier: NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd-IFNα/Syn3 (randomly assigned 1:1 to 1 × 10
Volume
35
Issue
30
First Page
3410
Last Page
3416
ISSN
1527-7755
Published In/Presented At
Shore, N. D., Boorjian, S. A., Canter, D. J., Ogan, K., Karsh, L. I., Downs, T. M., Gomella, L. G., Kamat, A. M., Lotan, Y., Svatek, R. S., Bivalacqua, T. J., Grubb, R. L., 3rd, Krupski, T. L., Lerner, S. P., Woods, M. E., Inman, B. A., Milowsky, M. I., Boyd, A., Treasure, F. P., Gregory, G., … Dinney, C. P. N. (2017). Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(30), 3410–3416. https://doi.org/10.1200/JCO.2017.72.3064
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
28834453
Department(s)
Administration and Leadership
Document Type
Article